Pirfenidone provides antifibrotic and anti-inflammatory properties for managing pulmonary conditions. This chemical agent inhibits growth factors and collagen synthesis to slow down the accumulation of excessive fibrotic tissue in the lungs.
Targeting abnormal tissue growth, Pirfenidone belongs to the pyridone family and acts as an anti-fibrotic agent. The substance interferes with processes that lead to scar formation in the lungs, helping to slow functional decline. It appears as the active component in the marketed product Esbriet, which is approved for use in Singapore under the Health Sciences Authority (HSA).
Designed to modulate cellular signaling, the compound reduces the release of pro-inflammatory chemicals that drive fibrotic pathways. By dampening these signals, it limits the accumulation of excess collagen that stiffens lung tissue. Clinical development highlighted its role in managing chronic fibrotic disorders rather than curing them.
In the context of therapeutic options, this medication occupies a niche for patients whose lung function is progressively compromised. It does not replace other supportive measures such as pulmonary rehabilitation or oxygen therapy.
Appearing in hard-gel capsules, this agent is sold under the brand name Esbriet and is also available as a generic formulation in Singapore. Both versions contain the same active molecule but may differ in excipients and price points set by local pharmacies. The HSA requires that each product meet stringent quality standards before distribution.
Manufacturers typically offer the capsules in strengths of 267 mg and 801 mg, allowing clinicians to tailor the total daily dose. While branded versions often carry the original label, generic packs bear the name of the supplying company and include a product insert with local safety information.
Patients receive the medication through prescription channels, ensuring that pharmacists provide the appropriate counseling sheet at dispensing.
Addressing scarring of lung tissue, the drug is primarily indicated for idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease.
Supporting individuals with other fibrotic lung disorders, clinicians may consider it for certain cases of chronic hypersensitivity pneumonitis when alternative therapies are insufficient.
Exploratory trials have examined its potential in systemic sclerosis-related lung involvement, though regulatory approval for that use remains pending.
Research continues into hepatic and renal fibrotic conditions, but current labeling limits its application to pulmonary contexts in Singapore.
Modulating cellular activity, the compound reduces fibroblast proliferation, which are cells responsible for producing scar tissue.
It also lessens the synthesis of collagen, the primary structural protein that accumulates in fibrotic lungs.
By lowering oxidative stress and inhibiting inflammatory mediators, the substance creates an environment less favorable for tissue stiffening.
These combined actions help preserve lung elasticity, allowing patients to maintain a steadier breathing capacity over time.
Mild gastrointestinal upset, such as nausea or loss of appetite, commonly appears during the initial weeks of therapy.
Transient skin reddening or heightened sensitivity to sunlight may occur, prompting users to apply sunscreen during outdoor activities.
Rarely, the substance can cause liver enzyme elevations indicating possible hepatic injury; monitoring is recommended.
Severe skin eruptions, including blistering rashes, require immediate medical attention and discontinuation of the product.
Pregnant or breastfeeding individuals should avoid exposure due to limited safety data.
Patients with pre-existing severe liver impairment or known hypersensitivity to pyridone derivatives must not use the medication.
Concurrent use of strong CYP1A2 inhibitors, such as fluvoxamine, can raise plasma levels and increase adverse-event risk.
Alcohol consumption may intensify liver-related concerns, so limiting intake is advisable.
For a complete interaction profile, refer to the specific medication’s product insert.
Storing the capsules at room temperature away from moisture preserves their stability throughout the treatment course.
Long-term therapy is typical, as the condition it addresses progresses slowly and benefits from continuous exposure to the active compound.
Different manufacturers may offer varied packaging sizes, influencing how many tablets a patient receives per prescription cycle.
For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This educational overview of Pirfenidone provides general information and is not medical advice; individual medicines such as Esbriet differ in strength, formulation, and labeling, and the provider disclaims liability for any clinical application. Patients should consult the medication’s specific product insert and a licensed healthcare professional for personalized guidance.
